Co-Expression of Chicken IL-2 and IL-7 Enhances the Immunogenicity and Protective Efficacy of a VP2-Expressing DNA Vaccine against IBDV in Chickens

Huo, Shanshan; Zhang, Jianlou; Fan, Juan; Wang, Xing; Wu, Fengyang; Zuo, Yuanmei; Zhong, Fei

doi:10.3390/v11050476

Cited by 21 publications

(5 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subunit vaccines that do not contain complete viral particles and viral nucleic acid components have become a new direction for the development of vaccines. VP2, the main host-protective antigen of IBDV, is usually used as an immunogen of subunit vaccines to elicit a protective immune response to IBDV [ 8 , 32 ]. Several expression systems, including yeast [ 33 , 34 ], insect cells [ 35 ], mammalian cells [ 29 ], plant cells [ 36 , 37 ], and E. coli [ 38 ] have been used to produce the VP2 of IBDV.…”

Section: Discussionmentioning

confidence: 99%

Development of a Viral-Like Particle Candidate Vaccine Against Novel Variant Infectious Bursal Disease Virus

et al. 2021

View full text Add to dashboard Cite

Infectious bursal disease (IBD), an immunosuppressive disease of young chickens, is caused by infectious bursal disease virus (IBDV). Novel variant IBDV (nVarIBDV), a virus that can evade immune protection against very virulent IBDV (vvIBDV), is becoming a threat to the poultry industry. Therefore, nVarIBDV-specific vaccine is much needed for nVarIBDV control. In this study, the VP2 protein of SHG19 (a representative strain of nVarIBDV) was successfully expressed using an Escherichia coli expression system and further purified via ammonium sulfate precipitation and size-exclusion chromatography. The purified protein SHG19-VP2-466 could self-assemble into 25-nm virus-like particle (VLP). Subsequently, the immunogenicity and protective effect of the SHG19-VLP vaccine were evaluated using animal experiments, which indicated that the SHG19-VLP vaccine elicited neutralization antibodies and provided 100% protection against the nVarIBDV. Furthermore, the protective efficacy of the SHG19-VLP vaccine against the vvIBDV was evaluated. Although the SHG19-VLP vaccine induced a comparatively lower vvIBDV-specific neutralization antibody titer, it provided good protection against the lethal vvIBDV. In summary, the SHG19-VLP candidate vaccine could provide complete immune protection against the homologous nVarIBDV as well as the heterologous vvIBDV. This study is of significance to the comprehensive prevention and control of the recent atypical IBD epidemic.

show abstract

Section: Discussionmentioning

confidence: 99%

Development of a Viral-Like Particle Candidate Vaccine Against Novel Variant Infectious Bursal Disease Virus

et al. 2021

View full text Add to dashboard Cite

show abstract

“…A complete understanding of the molecular mechanism of the host response against IBDV infection would be of great help in the development of antiviral strategies. Of note, the development of new adjuvants to improve vaccines’ immunogenicity is an effective alternative to protect chickens against IBDV infection, since chIL-2 and chIL-7 cytokines were effective biological adjuvants that enhanced the immunogenicity of the IBDV DNA vaccine [ 155 ]. In the IBDV–host interaction, some cellular proteins play an antiviral role through different mechanisms; for example, eIF4AII, NF45, CyPA, and TRIM25 suppressed IBDV replication by interacting with viral proteins or the replication complex, while HSP90AA1, p62, and SQSTM1 inhibited IBDV replication by interacting with viral proteins or genomes to initiate host autophagy, which subsequently induced their autophagic degradation.…”

Section: Discussionmentioning

confidence: 99%

Host Combats IBDV Infection at Both Protein and RNA Levels

Zhang

Zheng

2022

Viruses

View full text Add to dashboard Cite

Infectious bursal disease (IBD) is an acute, highly contagious, and immunosuppressive avian disease caused by infectious bursal disease virus (IBDV). In recent years, with the emergence of IBDV variants and recombinant strains, IBDV still threatens the poultry industry worldwide. It seems that the battle between host and IBDV will never end. Thus, it is urgent to develop a more comprehensive and effective strategy for the control of this disease. A better understanding of the mechanisms underlying virus–host interactions would be of help in the development of novel vaccines. Recently, much progress has been made in the understanding of the host response against IBDV infection. If the battle between host and IBDV at the protein level is considered the front line, at the RNA level, it can be taken as a hidden line. The host combats IBDV infection at both the front and hidden lines. Therefore, this review focuses on our current understanding of the host response to IBDV infection at both the protein and RNA levels.

show abstract

“…The quantification of serum antibodies against IBDV has traditionally been performed either by ELISA or through a neutralization assay in immortalized cells, such as DF‐1 cells (Huo et al., 2019 ; Ma et al., 2019 ), using a cell‐culture‐adapted viral strain, D78 (Sadigh et al., 2018 ). Therefore, cell‐culture‐adapted viruses are often used as a surrogate for the quantification of antibody responses elicited by infection with field strains or by vaccines containing the VP2 from field strains (Sadigh et al., 2018 ).…”

Section: Commentarymentioning

confidence: 99%

An Infectious Bursal Disease Virus (IBDV) Reverse Genetics Rescue System and Neutralization Assay in Chicken B Cells

et al. 2023

View full text Add to dashboard Cite

Infectious bursal disease virus (IBDV) is a major threat to the productivity of the poultry industry due to morbidity, mortality, and immunosuppression that exacerbates secondary infections and reduces the efficacy of vaccination programs. Field strains of IBDV have a preferred tropism for chicken B cells, the majority of which reside in the bursa of Fabricius (BF). IBDV adaptation to adherent cell culture is associated with mutations altering amino acids in the hypervariable region (HVR) of the capsid protein, which affects immunogenicity and virulence. Until recently, this has limited both the application of reverse genetics systems for engineering molecular clones, and the use of in vitro neutralization assays, to cell-culture-adapted strains of IBDV. Here, we describe the rescue of molecular clones of IBDV containing the HVR from diverse field strains, along with a neutralization assay to quantify antibody responses against the rescued viruses, both using chicken B cells. These methods are readily adaptable to any laboratory with molecular biology expertise and negate the need to obtain wild-type strains.

show abstract

Co-Expression of Chicken IL-2 and IL-7 Enhances the Immunogenicity and Protective Efficacy of a VP2-Expressing DNA Vaccine against IBDV in Chickens

Cited by 21 publications

References 39 publications

Development of a Viral-Like Particle Candidate Vaccine Against Novel Variant Infectious Bursal Disease Virus

Development of a Viral-Like Particle Candidate Vaccine Against Novel Variant Infectious Bursal Disease Virus

Host Combats IBDV Infection at Both Protein and RNA Levels

An Infectious Bursal Disease Virus (IBDV) Reverse Genetics Rescue System and Neutralization Assay in Chicken B Cells

Contact Info

Product

Resources

About